文献速递神经眼科

水通道蛋白4与髓鞘少突胶质细胞糖蛋白抗体时代视神经炎的人群发病率

Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies.
PubMed 文献 · Am J Ophthalmol · 2020-07-21

该研究回顾性分析2000年至2018年明尼苏达州奥姆斯特德县所有视神经炎患者,发现年发病率为3.9/10万,其中多发性硬化占57%,AQP4-IgG和MOG-IgG相关视神经炎合计占9%,且均与复发相关,但MOG-IgG视神经炎视力预后优于AQP4-IgG视神经炎。

要点

  • 视神经炎年发病率为3.9/10万,多发性硬化仍为主要病因(57%)。
  • AQP4-IgG和MOG-IgG相关视神经炎合计占9%,均易复发。
  • MOG-IgG视神经炎最终视力均≥20/30,优于AQP4-IgG视神经炎。

核心结论

  • 在人群水平,AQP4-IgG和MOG-IgG相关视神经炎占9%,均与复发相关,但MOG-IgG视神经炎视力预后优于AQP4-IgG视神经炎。

主要发现

  • 视神经炎年发病率为3.9/10万。
  • 最终诊断:多发性硬化57%,特发性29%,MOG-IgG相关疾病5%,AQP4-IgG血清阳性NMOSD 3%,感染性2%,结节病2%,血清阴性NMOSD 1%,药物相关1%。
  • 3例AQP4-IgG阳性患者均发生多次视神经炎,其中2例至少一眼残留无光感视力。
  • 6例MOG-IgG阳性患者中4例复发,全部6例最终视力≥20/30。

关键数值与推荐

  • AQP4-IgG和MOG-IgG相关视神经炎合计占9%。
  • AQP4-IgG阳性患者全部复发,2/3残留无光感视力。
  • MOG-IgG阳性患者4/6复发,最终视力全部≥20/30。

临床怎么用

  • 对视神经炎患者应检测AQP4-IgG和MOG-IgG以明确病因及复发风险。
  • AQP4-IgG阳性者需警惕多次复发及严重视力损害。
  • MOG-IgG阳性者虽易复发,但视力预后通常较好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To re-evaluate the population-based incidence of optic neuritis in the era of aquaporin-4-immunoglobulin G (AQP4-IgG) and myelin oligodendrocyte glycoprotein (MOG)-IgG, which are biomarkers of optic neuritis that is distinct from multiple sclerosis (MS). Over the past 15 years, 2 new biomarkers have been discovered that allow for further characterization of the cause of atypical optic neuritis: AQP4-IgG and MOG-IgG. DESIGN: Retrospective, population-based cohort. SETTING: population-based. PARTICIPANTS: all residents of Olmsted County, Minnesota, with optic neuritis diagnosed between January 1, 2000, and December 31, 2018. METHODS: The Rochester Epidemiology Project database was used to identify patients. Sera were tested for AQP4-IgG and MOG-IgG by using a live-cell-based flow cytometry assay. Main outcome measurements were the incidence and cause of optic neuritis. RESULTS: Optic neuritis was diagnosed in 110 patients, providing an annual incidence of 3.9 per 100,000. The final diagnosis was MS in 57%, idiopathic in 29%, MOG-IgG-associated disorder in 5%, AQP4-IgG-seropositive neuromyelitis optic spectrum disorder (NMOSD) in 3%, infectious type in 2%, sarcoidosis in 2%, seronegative NMOSD in 1%, and medication-related in 1%. All 3 patients positive for AQP4-IgG had more than 1 optic neuritis attack, 2 with residual no light perception vision in at least 1 eye. Among MOG-IgG-positive patients, 4 of 6 patients had recurrent optic neuritis, and all 6 had a final visual acuity of 20/30 or better. CONCLUSIONS: At a population level, AQP4-IgG and MOG-IgG account for 9% of optic neuritis and are associated with recurrent attacks, but MOG-IgG optic neuritis has a better visual outcome than AQP4-IgG optic neuritis.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hassan MB, Stern C, Flanagan EP, et al. Population-Based Incidence of Optic Neuritis in the Era of Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies. Am J Ophthalmol. 2020. PMID: 32707199. doi:10.1016/j.ajo.2020.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。